

Title

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders

Authors

Dalin Li, PhD¹, Alexander Xu, PhD², Emebet Mengesha, BS¹, Rebecca Elyanow, PhD³, Rachel M. Gittelman, PhD³, Heidi Chapman, PhD³, John C. Prostko, MS⁴, Edwin C. Frias, MBA⁴, James L. Stewart, PhD⁴, Valeriya Pozdnyakova, BS¹, Philip Debbas, BS¹, Angela Mujukian, M.D.¹, Arash A Horizon, MD⁵, Noah Merin, MD, PhD², Sandy Joung, MHDS⁶, Gregory J. Botwin, BS¹, Kimia Sobhani, PhD⁷, Jane C. Figueiredo, PhD², Susan Cheng, MD, MMSc, MPH⁶, Ian M. Kaplan, PhD³, Dermot P.B. McGovern, MB BS, D Phil¹, Akil Merchant, MD², Gil Y. Melmed, MD, MS¹, Jonathan Braun, MD, PhD^{1,7*}

Author Affiliations

1. F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2. Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
3. Adaptive Biotechnologies, Seattle, WA, USA.
4. Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL
5. Center for Rheumatology Medical Group, Los Angeles, CA, USA
6. Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
7. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Contact information

Jonathan Braun, MD, PhD
Inflammatory Bowel and Immunobiology Research Institute
Karsh Division of Digestive and Liver Diseases
Department of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA 90048
310-423-8717
jonathan.braun2@cshs.org

1 **Abstract**

2 **Background:** Vaccination against SARS-CoV-2 is a highly effective strategy to protect against
3 infection, which is predominantly mediated by vaccine-induced antibodies. Postvaccination
4 antibodies are robustly produced by those with inflammatory bowel disease (IBD) even on
5 immune-modifying therapies but are blunted by anti-TNF therapy. In contrast, T-cell response
6 which primarily determines long-term efficacy against disease progression, is less well
7 understood. We aimed to assess the post-vaccination T-cell response and its relationship to
8 antibody responses in patients with inflammatory bowel disease (IBD) on immune-modifying
9 therapies. **Methods:** We evaluated IBD patients who completed SARS-CoV-2 vaccination using
10 samples collected at four time points (dose 1, dose 2, 2 weeks after dose 2, 8 weeks after dose 2).
11 T-cell clonal analysis was performed by T-cell Receptor (TCR) immunosequencing. The breadth
12 (number of unique sequences to a given protein) and depth (relative abundance of all the unique
13 sequences to a given protein) of the T-cell clonal response were quantified using reference
14 datasets and were compared to antibody responses. **Results:** Overall, 303 subjects were included
15 (55% female; 5% with prior COVID) (Table). 53% received BNT262b (Pfizer), 42% mRNA-
16 1273 (Moderna) and 5% Ad26CoV2 (J&J). The Spike-specific clonal response peaked 2 weeks
17 after completion of the vaccine regimen (3- and 5-fold for breadth and depth, respectively); no
18 changes were seen for non-Spike clones, suggesting vaccine specificity. Reduced T-cell clonal
19 depth was associated with chronologic age, male sex, and immunomodulator treatment. It was
20 preserved by non-anti-TNF biologic therapies, and augmented clonal depth was associated with
21 anti-TNF treatment. TCR depth and breadth were associated with vaccine type; after adjusting
22 for age and gender, Ad26CoV2 (J&J) exhibited weaker metrics than mRNA-1273 (Moderna)
23 (p=0.01 for each) or BNT262b (Pfizer) (p=0.056 for depth). Antibody and T-cell responses were

24 only modestly correlated. While those with robust humoral responses also had robust TCR clonal
25 expansion, a substantial fraction of patients with high antibody levels had only a minimal T-cell
26 clonal response. **Conclusion:** Age, sex and select immunotherapies are associated with the T-cell
27 clonal response to SARS-CoV-2 vaccines, and T-cell responses are low in many patients despite
28 high antibody levels. These factors, as well as differences seen by vaccine type may help guide
29 reimmunization vaccine strategy in immune-impaired populations. Further study of the effects of
30 anti-TNF therapy on vaccine responses are warranted.

31 **Introduction**

32 Vaccination with mRNA or vector vaccines is immunogenic for SARS-CoV-2 and
33 protective for occurrence and severity of COVID-19. Anti-SARS-CoV-2 antibodies dominate
34 protection against initial infection^{1,2}, whereas T-cells play a larger role in preventing disease
35 progression^{3,4}. The T-cell clonal response to SARS-CoV-2 vaccines in immunologically
36 impaired individuals is poorly understood, as are effects of risk-factors on this aspect of the
37 vaccine response. Here, a cohort of inflammatory bowel disease (IBD) patients are assessed for
38 their clonal T-cell vaccine response, and its alteration by demographic factors and
39 immunotherapy.

41 **Methods**

42 The TCR clonal response to SARS-CoV-2 vaccines was assessed in 303 individuals with
43 IBD, enrolled in a prospective registry at Cedars-Sinai between January and June 2021. Samples
44 were collected longitudinally at the time of dose 1, dose 2, and 2 and 8 weeks after dose 2.

45 Subjects: Inflammatory bowel disease patients (N=303) were recruited in Los Angeles,
46 CA, USA between January and June 2021 under the CORALE-IBD protocol approved by the
47 Cedars Sinai Institutional Regulatory Board. Details of this cohort were recently reported^{5,6}.
48 Participants completed baseline surveys detailing demographics and medical history at the time
49 of vaccination, and were offered blood sampling after dose 1 (from 5 days after dose 1 until the
50 day of dose 2), after dose 2 (from 2 to 13 days after dose 2), and at 2 weeks (14 to 29 days after
51 dose 2), and 8 weeks (30 to 84 days after dose 2). Prior COVID-19 status was defined by
52 positive IgG(N) at any timepoint, or individuals with a prior clinical diagnosis of COVID-19.
53 COVID-19 experienced individuals were excluded from analysis except where specifically

54 noted. Most participants received mRNA vaccines, and except where indicated, analysis was
55 restricted to this subgroup.

56 Antibody assessment: Plasma antibodies to the receptor binding domain of the S1
57 subunit of the viral spike protein [IgG(S-RBD)] were quantified using the SARS-CoV-2 IgG-II
58 assay (Abbott Labs, Abbott Park, IL). as previously described ⁵.

59 T cell clonal analysis. Immunosequencing of the CDR3 regions of human TCR β chains
60 was performed on blood genomic DNA using the immunoSEQ Assay (Adaptive
61 Biotechnologies), which includes bias-controlled multiplex PCR, high-throughput sequencing,
62 and identification and quantitation of absolute abundance of unique TCR β CDR3 regions, and
63 quantitation of the corresponding T cell fractions by template count normalization⁷. Attribution
64 of TCR sequences to SARS-CoV-2 spike or other non-spike SARS-CoV-2 protein specificities
65 were assigned as described by Alter et al. and Sinder et al. ^{8,9}. The breadth summary metric was
66 calculated as the number of unique annotated rearrangements among total number of unique
67 productive rearrangements in the individual sample's dataset. The depth metric was calculated
68 by combining two elements; (a) the raw frequency of each rearrangement in the total repertoire
69 in the individual sample's dataset, and an estimate of clonal generations of the lineage
70 represented by each rearrangement. The resultant depth metric estimates the relative number of
71 clonal expansion generations across the TCRs, normalized by the total number of TCRs
72 sequenced in the sample. Hence, the metric can range from negative to positive values⁹.

73 Data analysis. Comparison of TCR breadth and depth used Mixed Linear Model across
74 time points and Generalized Linear Model within time points. Where possible, inverse normal
75 transformation was performed, and age and sex were included as covariates. Confidence
76 intervals for binomial probabilities were computed using exact methods. Geometric means and

77 confidence intervals were calculated for the log-transformed antibody levels. Other analyses are
78 specified in the individual figures. Analyses were restricted to individuals with mRNA vaccines
79 and no prior COVID-19 experience unless stated otherwise.

80 Data availability. Requests for de-identified data may be directed to the corresponding
81 authors (J.B., G.M.) and will be reviewed by the Office of Research Administration at Cedars-
82 Sinai Medical Center before issuance of data sharing agreements. Data limitations are designed
83 to ensure patient and participant confidentiality.

84

85 **Results**

86 Demographics and clinical metadata are summarized in Table 1. The T-cell clonal
87 response to vaccination across different time points is shown in Figure 1A. At dose 1, spike-
88 specific breadth and depth of SARS-CoV-2 clones were low (reflecting their basal level in an
89 individual's repertoire). Levels peaked two weeks post second vaccination ($P=4.64E-25$ and
90 $2.42E-25$ relative to dose 1 levels, for breadth and depth, respectively). From this peak, levels
91 declined at 8 weeks post second vaccination but were still significantly elevated (relative to dose
92 1, $1.08E-11$ and $5.30E-14$, for breadth and depth respectively). In contrast, no changes were
93 observed in T-cell clonal metrics for non-spike clones, demonstrating the specificity of the
94 vaccine responses.

95 Spike-specific T-cell and antibody responses were compared at week 2 post dose 2,
96 which corresponds to the peak of both antibody and T-cell vaccine responses¹⁰⁻¹² (Figure 1B).
97 The two responses were significantly but only moderately correlated ($R = 0.19$ to 0.21). Among
98 those with low antibody response, T-cell clonal breadth and depth were low, suggesting that
99 those with impaired humoral vaccine response have similarly impaired cellular responses.

100 However, among individuals with the lowest T-cell response, the majority discordantly had
101 moderate or high antibody levels.

102 The spike-specific clonal breadth was preserved across age groups, but clonal depth
103 reduced substantially with age (Figure 2A, $P=3.62E-4$ for trend test). There was no statistically
104 significant association between sex and spike T-cell clonal responses at 2 weeks after dose 2
105 (eFigure 1). However, at 8 weeks the T-cell clonal response was increased in females versus
106 males ($P=0.083$ and 0.0077 , for breadth and depth respectively).

107 IBD disease type (Crohn's disease vs. ulcerative colitis) had minimal effects on the
108 temporal kinetics or levels of spike T-cell clonal response to vaccines (eFigure 2). T-cell clonal
109 depth was significantly but selectively affected by suppressive immunotherapy (Figure 2B,
110 ANOVA $p=0.018$). There were no significant effects of anti-IL12/23, anti-integrin, or
111 steroids/small molecular treatments in comparison to patients with no immune treatments.
112 Interestingly, we observed an augmentation with anti-TNF ($p=0.0174$) after adjustment for age
113 and sex, with consistent trends in anti-TNF monotherapy or in combination with
114 immunomodulators.

115 No significant differences were observed between the T-cell clonal responses to the two
116 mRNA vaccines assessed in this cohort at 2 weeks after dose 2, although a marginal difference
117 was observed at 8 weeks for clonal breadth favoring mRNA-1273 ($P=0.047$, eFigure 3).
118 Compared to mRNA vaccination, Ad26.COV2.S induced a smaller spike T-cell clonal response
119 at both 2 weeks and 8 weeks after the single vaccination dose.

120 As expected, COVID-19 experienced subjects at dose 1 had significantly increased clonal
121 T-cell breadth and depth compared to COVID-19 naïve subjects (eFigure 4). However, no

122 significant differences were observed between experienced and naïve subjects in the peak TCR
123 response (2 weeks).

124

125 **Discussion**

126 This study assesses the T-cell clonal response to SARS-CoV-2 vaccine, to directly
127 enumerate SARS-CoV-2 spike-specific T-cell clonal diversity (breadth) and clone size (depth) in
128 immune-impaired individuals. Interrogation of our IBD patient cohort permitted assessment
129 under select and discrete modes of therapeutic immunosuppression. Few studies have assessed
130 the T-cell response to SARS-CoV-2 vaccines, and with few exceptions¹² have used methods that
131 enumerate SARS-CoV-2-specific T-cells based on peptide-stimulated cytokine production^{10, 11,}
132^{13, 14}. Such studies don't permit assessment of repertoire diversity and clonal size, important
133 factors in protective T-cell immunity^{3, 4}.

134 Consistent with reported kinetics of polyclonal functional T-cell response to vaccination
135¹⁰⁻¹², T-cell clonal response peaked two weeks after the second vaccination dose. Although
136 antibody response also peaks at 2 weeks⁵, antibody levels provided limited predictiveness for
137 the T-cell clonal response induced by vaccination, particularly for individuals with a low T-cell
138 response. This is consistent with findings reported from polyfunctional T-cell assessment^{10, 11, 13,}
139¹⁴. In the context of reimmunization strategies, T-cell assessment may be important to evaluate
140 both initial vaccine response and persistence of immunity after vaccination^{15, 16}.

141 We observed that as age increased, clonal depth in T-cell response to COVID-19 vaccine
142 decreased while clonal breadth was unaffected. This suggests that the potential spike-specific T-
143 cell repertoire is maintained with age, but the burst size of the clonal response is curtailed, an
144 observation previously reported in the global and influenza T-cell repertoire^{17, 18}. The T-cell

145 clonal response was reduced 8 weeks post vaccination in males, mostly via the impact on clonal
146 depth.

147 Immune-modifying therapy also reduced the T-cell response, again via its selective effect
148 on clonal depth, and thus the capacity of potential clones to expand after vaccination. In contrast,
149 the T-cell response was preserved with biologic therapies targeting IL12/23 and integrins, and
150 paradoxically augmented by anti-TNF therapy. If confirmed, this may reflect a differential effect
151 of anti-TNF therapy on T-cell clonal expansion and effector states besides cytokine production.

152 Taken together, these observations on age, sex, and immunotherapies have potential
153 significance when considering groups to prioritize for SARS-CoV-2 reimmunization. We also
154 observed suggestive signals for vaccine type on the T-cell clonal response, analogous to the
155 reduced levels of antibody response with Ad26.SARS.CoV.2 in this same cohort ⁵. Due to the
156 small number of Ad26.SARS.CoV.2 recipients studied, those differences should be interpreted
157 with caution.

158 Limitations of this study include a cohort of only individuals with IBD, lack of racial
159 diversity, and a tertiary center population, which reduce generalizability. Furthermore, direct
160 TCR sequencing detects only a minor subset of index antigen-reactive clones among the much
161 larger number of private clones ⁷.

162

163 **Conclusion**

164 Age, sex and select immunotherapies might be associated with the T-cell clonal response
165 to SARS-CoV-2 vaccines. A low T-cell response is poorly predicted by antibody levels.

166

167 **Acknowledgements**

168 This study was supported by the Leona M. and Harry B. Helmsley Charitable Trust, the
169 Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the
170 National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and
171 U01DK062413, the Cedars-Sinai Precision Health Initiative, the Erika J. Glazer Family
172 Foundation, and through the Serological Sciences Network, grant NCI U54-CA260591.

173 We thank all those who have contributed to the CORALE-IBD Vaccine study:

174 James Beekley, Sarah Contreas, Joseph Ebinger, Ergueen Herrera, Amy Hoang, Nathalie
175 Nguyen, Sarah Sternbach, Nancy Sun, Min Wu, Keren Appel, Andrea Banty, Edward Feldman,
176 Christina Ha, Dmitry Karayev, Benjamin Kretzman, Rashmi Kumar, Susie Lee, Shervin
177 Rabizadeh, Theodore Stein, Gaurav Syal, Stephan Targan, Eric Vasiliauskas, David Ziring,
178 Brigid Boland, Mary Hanna, Elizabeth Khanishian, Melissa Hampton, Justina Ibrahim, Ashley
179 Porter, Shane White, Cindy Zamudio.

180

181 **Author Contributions**

182

183 These authors equally contributed to the study: Dalin Li and Alexander Xu; Jonathan Braun,
184 Dermot McGovern, Gil Melmed.

185

186 Acquisition of data: GM, JB, EM, DL, AX, GB, KS, AAH, HM, RE, RMG, HC, IMK,
187 JCP, ECF, JLS

188

189 Analysis and interpretation of data: all authors

190 Drafting of the manuscript: DL, JB

191 Critical revision of the manuscript for important intellectual content: all authors

192 Statistical analysis: DL, AX

193 Obtained funding: GM, JB, DM, SC, JCF

194 Study supervision: GM, JB, DM, AM

195

196 **Competing Interests**

197 GYM has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-

198 Meyers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi,

199 Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-

200 initiated study. JB has received research funding from Janssen. DM has consulted for Takeda,

201 Boehringer-Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer, and Gilead, and is a

202 consultant/stockholder for Prometheus Biosciences.

203 References

- 204
- 205 1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
206 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. Jul
207 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
 - 208 2. Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against
209 SARS-CoV-2 in rhesus macaques. *Nature*. Oct 2020;586(7830):583-588. doi:10.1038/s41586-
210 020-2607-z
 - 211 3. Israelow B, Mao T, Klein J, et al. Adaptive immune determinants of viral clearance and
212 protection in mouse models of SARS-CoV-2. *bioRxiv*. May 19
213 2021;doi:10.1101/2021.05.19.444825
 - 214 4. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
215 rhesus macaques. *Nature*. Feb 2021;590(7847):630-634. doi:10.1038/s41586-020-03041-6
 - 216 5. Pozdnyakova V, Botwin GJ, Sobhani K, et al. Decreased Antibody Responses to
217 Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients with Inflammatory Bowel
218 Disease. *Gastroenterology*. Aug 12 2021;doi:10.1053/j.gastro.2021.08.014
 - 219 6. Botwin GJ, Li D, Figueiredo J, et al. Adverse Events After SARS-CoV-2 mRNA
220 Vaccination Among Patients With Inflammatory Bowel Disease. *Am J Gastroenterol*. Jun 21
221 2021;doi:10.14309/ajg.0000000000001342
 - 222 7. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell
223 receptor beta-chain diversity in alphabeta T cells. *Blood*. Nov 5 2009;114(19):4099-107.
224 doi:10.1182/blood-2009-04-217604
 - 225 8. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-
226 CoV-2 variants in humans. *Nature*. 2021 1August 12 2021;596(7871):268-272.
227 doi:10.1038/s41586-021-03681-2
 - 228 9. Snyder TM, Gittelman RM, Klinger M, et al. Magnitude and Dynamics of the T-Cell
229 Response to SARS-CoV-2 Infection at Both Individual and Population Levels. *medRxiv*.
230 2020:2020.07.31.20165647. doi:10.1101/2020.07.31.20165647
 - 231 10. Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to
232 SARS-CoV-2 vaccine BNT162b2. *Nature*. Aug 2021;596(7872):417-422. doi:10.1038/s41586-
233 021-03739-1
 - 234 11. Hadjadj J, Planas D, Ouedrani A, et al. Immunogenicity of BNT162b2 vaccine Against
235 the Alpha and Delta Variants in Immunocompromised Patients. *medRxiv*.
236 2021:2021.08.08.21261766. doi:10.1101/2021.08.08.21261766
 - 237 12. Oberhardt V, Luxenburger H, Kemming J, et al. Rapid and stable mobilization of CD8+
238 T cells by SARS-CoV-2 mRNA vaccine. *Nature*. Jul 28 2021;doi:10.1038/s41586-021-03841-4
 - 239 13. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted
240 immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine
241 BNT162b2: a cohort study. *Lancet Rheumatol*. Sep 2021;3(9):e627-e637. doi:10.1016/s2665-
242 9913(21)00212-5
 - 243 14. Agrati C, Castilletti C, Goletti D, et al. Coordinate Induction of Humoral and Spike
244 Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2
245 mRNA Vaccine. *Microorganisms*. Jun 16 2021;9(6)doi:10.3390/microorganisms9061315
 - 246 15. Israel A, Shenhar Y, Green I, et al. Large-scale study of antibody titer decay following
247 BNT162b2 mRNA vaccine or SARS-CoV-2 infection. *medRxiv*. 2021:2021.08.19.21262111.
248 doi:10.1101/2021.08.19.21262111

- 249 16. Pegu A, O'Connell S, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced
250 antibodies against SARS-CoV-2 variants. *Science*. Aug 12 2021;doi:10.1126/science.abj4176
251 17. Pizzolla A, Nguyen THO, Sant S, et al. Influenza-specific lung-resident memory T cells
252 are proliferative and polyfunctional and maintain diverse TCR profiles. *J Clin Invest*. 02/01/
253 2018;128(2):721-733. doi:10.1172/JCI96957
254 18. Qi Q, Liu Y, Cheng Y, et al. Diversity and clonal selection in the human T-cell
255 repertoire. *Proc Natl Acad Sci U S A*. 2014;111(36):13139. doi:10.1073/pnas.1409155111
256

	Total	Dose 1	Dose 2	2 Weeks	8 Weeks
n	303	110	158	153	184
race, n(%)					
Asian	7(2.36)	2(1.92)	3(1.94)	6(3.97)	3(1.64)
Black or African American	5(1.68)	2(1.92)	3(1.94)	4(2.65)	2(1.09)
Multiple	4(1.35)	2(1.92)	2(1.29)	2(1.32)	3(1.64)
Other	10(3.37)	3(2.88)	2(1.29)	6(3.97)	8(4.37)
Prefer not to answer	3(1.01)	1(0.96)	2(1.29)	2(1.32)	1(0.55)
White	268(90.24)	94(90.38)	143(92.26)	131(86.75)	166(90.71)
Hispanic , n(%)	15(5.05)	7(6.73)	8(5.16)	9(5.96)	9(4.92)
Gender, female n(%)	166(55.89)	58(55.77)	88(56.77)	80(52.98)	106(57.92)
Vaccine type, n(%)					
BNT162 (Pfizer/BioNtech)	160(52.81)	67(60.91)	90(56.96)	79(51.63)	97(52.72)
JNJ-78436725 (Johnson & Johnson)	15(4.95)	9(8.18)	-	9(5.88)	13(7.07)
mRNA-1273 (Moderna/NIH)	128(42.24)	34(30.91)	68(43.04)	65(42.48)	74(40.22)
Prior COVID-19 History, n(%)	15(5.08)	6(5.88)	6(3.9)	5(3.33)	6(3.3)
Treatments, n(%)					
No Immune suppression	48(16.22)	15(14.02)	28(18.18)	22(14.57)	29(16.11)
Anti-TNF	104(35.14)	35(32.71)	54(35.06)	54(35.76)	65(36.11)
Other biologics (anit-IL23, anti-integrin)	126(42.57)	48(44.86)	64(41.56)	66(43.71)	75(41.67)
Immunomodulators	18(6.08)	9(8.41)	8(5.19)	9(5.96)	11(6.11)
COVID-19 TCR matrices, mean(s.d.)					
clonal breadth	2.05e-04(1.42e-04)	1.24e-04(1.26e-04)	2.03e-04(1.55e-04)	2.87e-04(1.51e-04)	1.93e-04(9.64e-05)
clonal depth	64.26(84.19)	22.26(49.83)	76.13(111.82)	102.45(92.14)	50.71(47.47)
clonal breadth, Spike only	4.49e-05(5.53e-05)	2.29e-05(2.99e-05)	5.04e-05(6.74e-05)	7.69e-05(6.43e-05)	4.35e-05(3.73e-05)
clonal depth, spike only	2.06(29.04)	-10.59(12.89)	5.86(41.77)	13.91(30.94)	-2.66(15.18)
Age group, n(%)					
<=30	44(14.52)	16(14.55)	28(17.72)	23(15.03)	23(12.5)
30-40	83(27.39)	31(28.18)	41(25.95)	48(31.37)	44(23.91)
40-50	71(23.43)	30(27.27)	38(24.05)	38(24.84)	36(19.57)
50-60	45(14.85)	14(12.73)	24(15.19)	25(16.34)	30(16.3)
>60	60(19.8)	19(17.27)	27(17.09)	19(12.42)	51(27.72)




Figure 1. T-cell clonal response and antibody levels to SARS-CoV-2 immunization. (A) T-cell clonal response to SARS-CoV-2 vaccination. Box plots show mean, quartiles, and data range. Relative to dose 1, p values (mixed-effect model analysis with adjustment for age and sex) for dose 2, 2 weeks post 2nd vaccination, and 8 weeks post 2nd vaccination were: breadth ($1.04\text{E-}8$, $4.64\text{E-}25$, $1.08\text{E-}11$); depth ($9.87\text{E-}11$, $2.42\text{E-}25$, $5.30\text{E-}14$). (B) Comparison of T-cell clonal response metrics to anti-spike IgG levels (Spearman's Correlation).







Figure 2. Effect of age and immunologic treatment on T-cell clonal response. (A) Age. Numbers of subjects by age group are tabulated in Table 1. (B) Immunologic treatment. No Imm (no treatment, 5-aminosalicylates, rectal steroids; N=19), anti-Integrin (N=14), anti-IL23 (N=36), anti-TNF_mono (monotherapy with anti-TNF, N=36), anti-TNF_cmb (Combined therapy with anti-TNF and a thiopurine or methotrexate, N=11), steroids/small mol (systemic corticosteroids, or monotherapy with thiopurines, methotrexate, or Janus kinase (JAK) inhibitors, N=16). Boxes are mean value, bars are data range, and p-values were calculated by ANOVA after adjustment for age, sex, vaccine type and COVID history.




eFigure 1. Effect of gender on spike T cell clonal response to vaccination. (A) T cell clonal breadth at week 2 (left) or week 8 (right) post second vaccination. (B) T cell clonal depth at week 2 (left) or week 8 (right) post second vaccination. Box plots show mean, quartiles, and data range. P values were calculated using a mixed-effects model (with adjustment for age and gender) comparing dose 1 to either 2 weeks post 2nd vaccination (left) or 8 weeks (right) post 2nd vaccination.



eFigure 2. Effect of IBD disease type on spike T cell clonal response to vaccination. (A) T cell clonal breadth at week 2 (left) or week 8 (right) post second vaccination. (B) T cell clonal depth at week 2 (left) or week 8 (right) post second vaccination. CD, Crohn's disease; UC/IC, Ulcerative colitis and indeterminate colitis. Box plots show mean, quartiles, and data range. P values are a mixed model analysis (with adjustment for age and gender) comparing dose 1 to either 2 weeks post 2nd vaccination (left) or 8 weeks (right) post 2nd vaccination.



eFigure 3. Vaccine type and the T cell clonal spike response. T cell clonal spike responses were tabulated 2 weeks (A and C) or 8 weeks (B and D) after completion of vaccination regimen (two doses for mRNA vaccines, one dose for the vector vaccine). Subject numbers were Pfizer (BNT162b2, N=160), Moderna (mRNA-1273, N=128), JNJ (Ad26.COV2.S, N=15). P values were calculated using a mixed-effects model (with adjustment for age and gender) for the indicated comparisons.



eFigure 4. Effect of COVID-19 naïve and experienced status on T cell clonal response. The numbers of subjects were 288 (naïve) and 15 (experienced). (A) Dose 1; (B) Dose 2; (C) 2 weeks post second vaccination; (D) 8 weeks post second vaccination. Box plots show mean, quartiles, and data range. P values were generated from a mixed-effects model (with adjustment for age and gender) comparing naïve and experienced subjects.